CRISPR-Cas9 BCL11A enhancer disruption for SCD HBB c.20A>T: clinical evidence from exa-cel

CRISPR-Cas9-mediated disruption of the BCL11A erythroid-specific enhancer in autologous CD34+ HSPCs has demonstrated durable reactivation of fetal hemoglobin (HbF) and near-elimination of vaso-occlusive crises in patients homozygous for HBB c.20A>T (p.Glu7Val). Exagamglogene autotemcel (exa-cel/Casgevy) received FDA and MHRA approval in late 2023, representing the first approved CRISPR-based gene editing therapy for any disease.

The pivotal CLIMB-121 trial enrolled patients with severe sickle cell disease (≥2 vaso-occlusive crises/year). At 12+ months follow-up, 29 of 30 evaluable patients were free of VOCs, with sustained HbF levels >20% (mean ~40%). Edited CD34+ cells showed >80% allelic editing at the BCL11A enhancer. The mechanism bypasses the pathogenic HBB variant entirely by reactivating gamma-globin expression, which inhibits HbS polymerization. ClinVar classifies the c.20A>T variant (VCV000446735) as pathogenic with expert panel review. FDA approved exa-cel (Casgevy) in December 2023 under priority review.

Therapy requires myeloablative busulfan conditioning prior to infusion of edited cells, carrying significant toxicity including prolonged cytopenia and infertility risk. Long-term durability beyond 3-4 years is still being characterized. Off-target editing at the BCL11A locus has been assessed by GUIDE-seq and Digenome-seq but genome-wide off-target effects in engrafted cells require longer follow-up. Cost and manufacturing complexity limit accessibility in sub-Saharan Africa where SCD burden is highest. Patients with organ damage from prior crises may have limited benefit from HbF reactivation alone.